We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Imaging Agent with CT Scans Aids Brachytherapy

By HospiMedica staff writers
Posted on 02 Oct 2000
Researchers combined a radio-labeled monoclonal antibody with computed tomography (CT) scans to locate the highest areas of tumor burden in the prostate and then implanted radioactive seeds within those areas. The study was conducted by researchers from the University Hospitals of Cleveland (OH, USDA) and published in the International Journal of Radiation Oncology.

The radio-labeled monoclonal antibody is called ProstaScint, developed by Cytogen Corp. (Princeton, NJ, USA; www.cytogen.com). ProstaScint is currently used to help doctors determine whether prostate cancer has spread beyond the prostate gland. In the current study, ProstaScint's ability to bind a proprietary cancer marker (prostate-specific membrane antigen, or PSMA) on prostate cancer cells enabled doctors to deliver higher doses of radiation to regions with a higher tumor burden while sparing more-sensitive structures such as the urethra, rectum, and bladder.

Current diagnostic technologies such as magnetic resonance imaging (MRI) or CT only provide anatomical information and do not offer insight into the biology of cancer, said Rodney J. Ellis, M.D., director of brachytherapy at the University Hospitals of Cleveland and lead author of the study. Biological imaging will radically change current concepts in oncology.

Recently, Cytogen made an agreement with Draxis Health, Inc. (Toronto, Canada) to market and distribute Brachyseed implants for prostate cancer therapy. The implants are robotically manufactured by Draxis and may offer improved dosimetry and better patient safety, says Cytogen. The company is developing in-vivo immunotherapies for prostate cancer, including cancer vaccines and monoclonal antibody-based therapies.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Prostate Cancer MRI Analysis Tool
DynaCAD Urology
New
CPAP Machine
EcoStar Auto

Latest Patient Care News

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization